ACM
GILD icon

Armbruster Capital Management’s Gilead Sciences GILD Stock Holding History

Armbruster Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-40
Closed -$3K – 245
2017
Q4 		$3K Buy
+40
New +$3.04K ﹤0.01% 246
2016
Q2 		– Sell
-400
Closed -$37K – 299
2016
Q1 		$37K Hold
400
– – 0.03% 148
2015
Q4 		$40K Buy
+400
New +$41.6K 0.04% 147

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Armbruster Capital Management's GILD Position: Q1 2018 in Review

Armbruster Capital Management sold out of Gilead Sciences (GILD) in Q1 2018, closing a stake of 40 shares — an estimated $3K sold.

Armbruster Capital Management first reported a position in GILD in Q4 2015 and held it in 3 quarters. The position peaked at $40K in Q4 2015. 1,564 funds tracked by Wall St. Rank hold GILD as of Q1 2018.

  • Armbruster Capital Management reported no remaining Gilead Sciences position as of Q1 2018 after selling out during the quarter.
  • Armbruster Capital Management sold 40 Gilead Sciences shares in Q1 2018, an estimated $3K.
  • Armbruster Capital Management first reported a position in Gilead Sciences in Q4 2015 and held it in 3 quarters.
  • Armbruster Capital Management's Gilead Sciences position peaked at $40K in Q4 2015.
  • 1,564 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2018.

Based on Armbruster Capital Management's 13F filing for Q1 2018, filed 18 Apr 2018.